Suppressing NLRP3 inflammasome activity has been shown to alleviate the severity of GalN/LPS-triggered acute liver injury in mice, which mimics many characteristics of FHF in clinical settings [6,8]. This evidence concerns the gene GAL and TNF receptor 1-associated periodic fever syndrome.